Pachetka A, Adamek B, Strzelczyk JK, Krakowczyk , Migula P, Nowak P, et al
Retnakaran and colleagues say their data indicate that combining a GLP-1 agonist with basal insulin can achieve the ideal triumvirate of short-term outcomes in diabetes management: potent glucose-lowering capacity without increased hypoglycaemia or weight gain
This downtime allows the bodys enzymatic systems to reset and helps preserve responsiveness to NNMT inhibition
This case raised questions about whether GLP-1 medications might trigger autoimmune responses in susceptible individuals, adding another layer of complexity to an already nuanced picture
That said, understanding potential side effects, contraindications, and monitoring practices is essential for using it safely and effectively
To discover your MetabolicPrint and start your journey with Found, take the quiz